
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9493986/publications.pdf Version: 2024-02-01



DANIEL I MEDINA

#	Article	IF	CITATIONS
1	Carcinoma-Associated Fibroblast–Like Differentiation of Human Mesenchymal Stem Cells. Cancer Research, 2008, 68, 4331-4339.	0.4	799
2	Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochemical Pharmacology, 2008, 76, 582-588.	2.0	431
3	Increased sensitivity to the hepatocarcinogen diethylnitrosamine in transgenic mice carrying the hepatitis B virusX gene. Molecular Carcinogenesis, 1996, 15, 261-269.	1.3	171
4	Stage-specific changes in SR splicing factors and alternative splicing in mammary tumorigenesis. Oncogene, 1999, 18, 3574-3582.	2.6	169
5	The mammary gland: A unique organ for the study of development and tumorigenesis. Journal of Mammary Gland Biology and Neoplasia, 1996, 1, 5-19.	1.0	168
6	Nuclear Factor-κB (NF-κB) Regulates Proliferation and Branching in Mouse Mammary Epithelium. Molecular Biology of the Cell, 2001, 12, 1445-1455.	0.9	133
7	miR-320 targets transferrin receptor 1 (CD71) and inhibits cell proliferation. Experimental Hematology, 2009, 37, 245-255.	0.2	121
8	Biological and genetic properties of the p53 null preneoplastic mammary epithelium. FASEB Journal, 2002, 16, 881-883.	0.2	111
9	Mammary developmental fate and breast cancer risk. Endocrine-Related Cancer, 2005, 12, 483-495.	1.6	105
10	A transgenic mouse model for mammary carcinogenesis. Oncogene, 1998, 16, 997-1007.	2.6	93
11	Progesterone, in Addition to Estrogen, Induces Cyclin D1 Expression in the Murine Mammary Epithelial Cell, in Vivo*. Endocrinology, 1997, 138, 3933-3939.	1.4	90
12	Extracellular Matrix Metalloproteinase Inducer (CD147) Confers Resistance of Breast Cancer Cells to Anoikis through Inhibition of Bim. Journal of Biological Chemistry, 2006, 281, 9719-9727.	1.6	87
13	Expression of a p53 mutant in the epidermis of transgenic mice accelerates chemical carcinogenesis. Oncogene, 1998, 17, 35-45.	2.6	80
14	Hormone dependence in premalignant mammary progression. Cancer Research, 2003, 63, 1067-72.	0.4	78
15	Breast Cancer. Clinical Cancer Research, 2004, 10, 380s-384s.	3.2	77
16	Macrophages promote the progression of premalignant mammary lesions to invasive cancer. Oncotarget, 2017, 8, 50731-50746.	0.8	75
17	Mesenchymal stromal cells protect mantle cell lymphoma cells from spontaneous and drug-induced apoptosis through secretion of B-cell activating factor and activation of the canonical and non-canonical nuclear factor ÂB pathways. Haematologica, 2012, 97, 1255-1263.	1.7	73
18	MMTV-Espl1 transgenic mice develop aneuploid, estrogen receptor alpha (ERα)-positive mammary adenocarcinomas. Oncogene, 2014, 33, 5511-5522.	2.6	66

#	Article	IF	CITATIONS
19	Differentiation-associated miR-22 represses Max expression and inhibits cell cycle progression. Biochemical and Biophysical Research Communications, 2010, 394, 606-611.	1.0	64
20	Infrequentp53 mutations in 7,12-dimethylbenz[a]anthracene–induced mammary tumors in BALB/c andp53 hemizygous mice. Molecular Carcinogenesis, 1994, 9, 175-183.	1.3	52
21	p96, a MAPK-related protein, is consistently downregulated during mouse mammary carcinogenesis. Oncogene, 1998, 17, 1173-1178.	2.6	52
22	p53 function is required for hormone-mediated protection of mouse mammary tumorigenesis. Cancer Research, 2003, 63, 6140-3.	0.4	51
23	Stromal Gas6 promotes the progression of premalignant mammary cells. Oncogene, 2019, 38, 2437-2450.	2.6	50
24	Bcl-2 expression delays mammary tumor development in dimethylbenz(a)anthracene-treated transgenic mice. Oncogene, 1999, 18, 6597-6604.	2.6	49
25	The preneoplastic phenotype in murine mammary tumorigenesis. Journal of Mammary Cland Biology and Neoplasia, 2000, 5, 393-407.	1.0	46
26	Mechanisms of Hormonal Prevention of Breast Cancer. Annals of the New York Academy of Sciences, 2001, 952, 23-35.	1.8	42
27	Accelerated appearance of chemically induced mammary carcinomas in obese yellow (<i>A</i> ^{<i>vy</i>} / <i>A</i>) (BALB/c X VY) F ₁ hybrid mice. Journal of Toxicology and Environmental Health - Part A: Current Issues, 1982, 10, 131-142.	1.1	41
28	Gene expression screening for specific genes associated with mouse mammary tumor development. Molecular Carcinogenesis, 1993, 8, 123-126.	1.3	39
29	Wild-Type N-Ras, Overexpressed in Basal-like Breast Cancer, Promotes Tumor Formation by Inducing IL-8 Secretion via JAK2 Activation. Cell Reports, 2015, 12, 511-524.	2.9	39
30	Evidence of separate pathways for viral and chemical carcinogenesis in c3h/stwi mouse mammary glands. International Journal of Cancer, 1980, 26, 373-379.	2.3	37
31	Chemical Carcinogenesis of Rat and Mouse Mammary Glands. Breast Disease, 2007, 28, 63-68.	0.4	35
32	Murine Mammary Tumor Virus Expression During Mammary Tumorigenesis in BALB/c Mice. Journal of Virology, 1979, 29, 483-493.	1.5	35
33	Tamoxifen Inhibition of Estrogen Receptor-α–Negative Mouse Mammary Tumorigenesis. Cancer Research, 2005, 65, 3493-3496.	0.4	33
34	Radiation-induced apoptosis in normal and pre-neoplastic mammary glandsin vivo: Significance of gland differentiation and p53 status. , 1996, 65, 466-472.		32
35	Biological and molecular characteristics of the premalignant mouse mammary gland. Biochimica Et Biophysica Acta: Reviews on Cancer, 2002, 1603, 1-9.	3.3	31
36	Stage specificity of selenium-mediated inhibition of mouse mammary tumorigenesis. Biological Trace Element Research, 1983, 5, 297-306.	1.9	30

#	Article	IF	CITATIONS
37	Antineoplastic Effects of Partially HLA-Matched Irradiated Blood Mononuclear Cells in Patients With Renal Cell Carcinoma. Journal of Clinical Oncology, 2003, 21, 3785-3791.	0.8	29
38	Of Mice and Women: A Short History of Mouse Mammary Cancer Research with an Emphasis on the Paradigms Inspired by the Transplantation Method. Cold Spring Harbor Perspectives in Biology, 2010, 2, a004523-a004523.	2.3	28
39	14-3-3ζ Orchestrates Mammary Tumor Onset and Progression via miR-221–Mediated Cell Proliferation. Cancer Research, 2014, 74, 363-373.	0.4	28
40	Progesterone, in Addition to Estrogen, Induces Cyclin D1 Expression in the Murine Mammary Epithelial Cell, in Vivo. Endocrinology, 1997, 138, 3933-3939.	1.4	28
41	Fulvestrant treatment alters MDM2 protein turnover and sensitivity of human breast carcinoma cells to chemotherapeutic drugs. Cancer Letters, 2014, 350, 52-60.	3.2	25
42	The transcription factor RUNX2 regulates receptor tyrosine kinase expression in melanoma. Oncotarget, 2016, 7, 29689-29707.	0.8	24
43	Premalignant and Malignant Mammary Lesions Induced by MMTV and Chemical Carcinogens. Journal of Mammary Gland Biology and Neoplasia, 2008, 13, 271-277.	1.0	23
44	Plitidepsin (Aplidin) is a potent inhibitor of diffuse large cell and Burkitt lymphoma and is synergistic with rituximab. Cancer Biology and Therapy, 2012, 13, 114-122.	1.5	23
45	Delay of dimethylbenz[a]anthracene-induced mammary tumorigenesis in transgenic mice by apoptosis induced by an unusual mutant p53 protein. Molecular Carcinogenesis, 1995, 14, 75-83.	1.3	22
46	Concurrent deregulation of gelsolin and cyclin D1 in the majority of human and rodent breast cancers. , 1999, 81, 930-938.		21
47	Isolation of St. Louis encephalitis virus from a killer whale. Clinical and Diagnostic Virology, 1993, 1, 109-112.	1.8	20
48	Partial Expression of Endogenous Mouse Mammary Tumor Virus in Mammary Tumors Induced in BALB/c Mice by Chemical, Hormonal, and Physical Agents. Journal of Virology, 1981, 38, 571-580.	1.5	20
49	Riluzole exerts distinct antitumor effects from a metabotropic glutamate receptor 1-specific inhibitor on breast cancer cells. Oncotarget, 2017, 8, 44639-44653.	0.8	20
50	Expression of Brca1 and splice variant Brca1î"11 RNA levels in mouse mammary gland during normal development and tumorigenesis. Oncogene, 2000, 19, 5237-5243.	2.6	19
51	Paracrine Met signaling triggers epithelial–mesenchymal transition in mammary luminal progenitors, affecting their fate. ELife, 2015, 4, .	2.8	19
52	Environmental carcinogens andp53 tumor-suppressor gene interactions in a transgenic mouse model for mammary carcinogenesis. Environmental and Molecular Mutagenesis, 2002, 39, 178-183.	0.9	18
53	Treatment of Multidrug Resistant (MDR1) Murine Leukemia with P-Glycoprotein Substrates Accelerates the Course of the Disease. Biochemical and Biophysical Research Communications, 1999, 266, 167-173.	1.0	17
54	Stroma is not a major target in DMBA-mediated tumorigenesis of mouse mammary preneoplasia. Journal of Cell Science, 2005, 118, 123-127.	1.2	17

#	Article	IF	CITATIONS
55	Cobblestone-Area Forming Cells Derived from Patients with Mantle Cell Lymphoma Are Enriched for CD133+ Tumor-Initiating Cells. PLoS ONE, 2014, 9, e91042.	1.1	17
56	Expression of MDM2 during mammary tumorigenesis. , 1999, 81, 292-298.		16
57	Radiation-induced tumorigenesis in preneoplastic mouse mammary glands in vivo: Significance ofp53 status and apoptosis. Molecular Carcinogenesis, 1998, 22, 199-207.	1.3	15
58	Nuclear Factor-κB Modulation in Patients Undergoing Induction Chemotherapy for Acute Myelogenous Leukemia. Clinical Cancer Research, 2008, 14, 7564-7568.	3.2	15
59	Spontaneous progression of hyperplastic outgrowths of the D1 lineage to mammary tumors: Expression of mouse mammary tumor virus and cellular proto-oncogenes. Molecular Carcinogenesis, 1989, 1, 229-238.	1.3	14
60	A Pilot study of allogeneic cellular therapy for patients with advanced hematologic malignancies. Leukemia Research, 2008, 32, 1842-1848.	0.4	14
61	Prevention of Tumorigenesis in p53-Null Mammary Epithelium by Rexinoid Bexarotene, Tyrosine Kinase Inhibitor Gefitinib, and Celecoxib. Cancer Prevention Research, 2009, 2, 168-174.	0.7	14
62	Mouse Mammary Intraductal (MIND) Method for Transplantation of Patient Derived Primary DCIS Cells and Cell Lines. Bio-protocol, 2016, 6, .	0.2	14
63	The effect of parity, tumor latency and transplantation on the activation ofint loci in mmtv-induced, transplanted C3H mammary pre-neoplasias and their tumors. International Journal of Cancer, 1992, 51, 805-811.	2.3	13
64	Stromal fibroblasts influence human mammary epithelial cell morphogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 4723-4724.	3.3	13
65	Hormones, chemicals and proviral gene expression as contributing factors during mammary carcinogenesis in C3H/StWi mice. International Journal of Cancer, 1981, 27, 81-86.	2.3	12
66	Activation of endogenous MMTV proviruses in murine mammary cajncer induced by chemical carcinogen. International Journal of Cancer, 1987, 40, 414-422.	2.3	12
67	Wnt-1 and int-2 mammary oncogene effects on the β-catenin pathway in immortalized mouse mammary epithelial cells are not sufficient for tumorigenesis. Oncogene, 2001, 20, 7645-7657.	2.6	12
68	Adenovirus Infection of Primary Malignant Lymphoid Cells. Leukemia and Lymphoma, 2002, 43, 37-49.	0.6	10
69	Levels and 75Se-Labeling of Specific Proteins as a Consequence of Dietary Selenium Concentration in Mice and Rats. Experimental Biology and Medicine, 1991, 196, 147-154.	1.1	9
70	Retinoblastoma Tumor Suppressor Gene Expression Determines the Response to Sequential Flavopiridol and Doxorubicin Treatment in Small-Cell Lung Carcinoma. Clinical Cancer Research, 2009, 15, 1232-1240.	3.2	9
71	Intra-mammary Ductal Transplantation: A Tool to Study Premalignant Progression. Journal of Mammary Gland Biology and Neoplasia, 2012, 17, 131-133.	1.0	9
72	Int6 reduction activates stromal fibroblasts to enhance transforming activity in breast epithelial cells. Cell and Bioscience, 2015, 5, 10.	2.1	9

#	Article	IF	CITATIONS
73	Reprogramming of the estrogen responsive transcriptome contributes to tamoxifen-dependent protection against tumorigenesis in the p53 null mammary epithelial cells. PLoS ONE, 2018, 13, e0194913.	1.1	9
74	Interactions between HIV-1 and Cytomegalovirus in Human Osteosarcoma Cells Carrying Both Viruses. AIDS Research and Human Retroviruses, 1993, 9, 519-527.	0.5	8
75	Introduction to this issue—Experimental models of development, function, and neoplasia. Journal of Mammary Gland Biology and Neoplasia, 1996, 1, 3-4.	1.0	8
76	Characterization and use of a recombinant retroviral system for the analysis of drug resistant HIV. Journal of Virological Methods, 1998, 71, 169-176.	1.0	8
77	Abstract CT139: Intratumoral oncolytic virus V937 in combination with pembrolizumab (pembro) in patients (pts) with advanced melanoma: Updated results from the phase 1b CAPRA study. Cancer Research, 2021, 81, CT139-CT139.	0.4	8
78	Reconstitution of Estrogen-Dependent Transcriptional Activation of an Adenoviral Target Gene in Select Regions of the Rat Mammary Gland. , 0, .		8
79	Does the Mouse Mammary Cland Arise from Unipotent or Multipotent Mammary Stem/Progenitor Cells?. Journal of Mammary Cland Biology and Neoplasia, 2018, 23, 1-3.	1.0	7
80	Mammary gland as a morphological end point in carcinogenesis studies. Journal of Toxicology and Environmental Health - Part A: Current Issues, 1976, 1, 551-560.	1.1	4
81	Introduction: models of premalignant breast disease. Journal of Mammary Gland Biology and Neoplasia, 2000, 5, 339-340.	1.0	4
82	Adenovirus infection and cytotoxicity of primary mantle cell lymphoma cells. Experimental Hematology, 2005, 33, 1337-1347.	0.2	4
83	Choline-magnesium trisalicylate modulates acute myelogenous leukemia gene expression during induction chemotherapy. Leukemia and Lymphoma, 2017, 58, 1227-1230.	0.6	4
84	Pepsin can be used to subculture viable mammary epithelial cells. In Vitro, 1983, 19, 730-734.	1.2	3
85	SELENIUM-MEDIATED INHIBITION OF CARCINOGENESIS. Phosphorous and Sulfur and the Related Elements, 1988, 38, 3-18.	0.2	3
86	Tyrosine phosphorylation in mouse mammary hyperplasias. Carcinogenesis, 1995, 16, 923-930.	1.3	3
87	Interaction of retinoblastoma protein and D cyclins during cell-growth inhibition by hexamethylenebisacetamide in TM2H mouse epithelial cells. Molecular Carcinogenesis, 1998, 22, 128-143.	1.3	3
88	Use of Floxuridine to Modulate the Antiviral Activity of Zidovudine. AIDS Research and Human Retroviruses, 1996, 12, 965-968.	0.5	2
89	Concurrent deregulation of gelsolin and cyclin D1 in the majority of human and rodent breast cancers. International Journal of Cancer, 1999, 81, 930-938.	2.3	1
90	Pituitary Isograft Transplantation in Mice. Bio-protocol, 2017, 7, e2317.	0.2	1

#	Article	IF	CITATIONS
91	Dedication: Clifford W. Welsch. Journal of Mammary Gland Biology and Neoplasia, 1996, 1, 135-136.	1.0	0
92	Use of recombinant viruses to assess the pattern of early human immunodeficiency virus breakthrough infection in the presence of stavudine. Journal of General Virology, 1999, 80, 2361-2367.	1.3	0
93	Whole Mammary Gland Transplantation in Mice Protocol. Bio-protocol, 2017, 7, .	0.2	О